Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.…
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
Wave Life Sciences (NASDAQ: WVE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 317 employees.
The shares were at 2.560 USD on 20 November 2026, down 64.7% over 52 weeks. Its 52-week range is 2.545 USD to 21.73 USD, and it trades at the bottom of that range.
Its market capitalisation is 504.91M USD.
Wave Life Sciences reports return on equity of -39.4%, an operating margin of -320.9% and revenue up 73.0% year over year.
It holds more cash than debt, a net cash position of 387.48M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.